加载中
HKSEHealthcareDrug Manufacturers - Specialty & Generic
最新数据
HK$0.178
+HK$0.005 · +2.89%
Huakang Biomedical Holdings Company Limited operates as an investment holding firm, primarily dedicated to the research, development, manufacturing, marketing, and distribution of in-vitro diagnostic (IVD) reagents within the People's Republic of China. Its comprehensive product portfolio encompasses IVD reagents designed for assessing male and female fertility, detecting parasite antibodies, and identifying the Epstein-Barr virus. Additionally, the company provides auxiliary reproductive supplies and equipment, alongside a range of healthcare products and nutritional supplements marketed under its 'Nutronic' brand, which are sold through both digital and physical platforms. Products are distributed directly to hospitals and medical institutions, as well as through a network of third-party distributors. The company was founded in 1992 and maintains its headquarters in Wan Chai, Hong Kong.
最新数据
HK$0.178
+HK$0.005 · +2.89%
盘中时间采用HKT。市场数据可能有所延迟。
Huakang Biomedical Holdings Company Limited operates as an investment holding firm, primarily dedicated to the research, development, manufacturing, marketing, and distribution of in-vitro diagnostic (IVD) reagents within the People's Republic of China. Its comprehensive product portfolio encompasses IVD reagents designed for assessing male and female fertility, detecting parasite antibodies, and identifying the Epstein-Barr virus. Additionally, the company provides auxiliary reproductive supplies and equipment, alongside a range of healthcare products and nutritional supplements marketed under its 'Nutronic' brand, which are sold through both digital and physical platforms. Products are distributed directly to hospitals and medical institutions, as well as through a network of third-party distributors. The company was founded in 1992 and maintains its headquarters in Wan Chai, Hong Kong.
日内区间
当前HK$0.178
52周区间
当前HK$0.178
盘中时间采用HKT。市场数据可能有所延迟。
Huakang Biomedical Holdings Company Limited operates as an investment holding firm, primarily dedicated to the research, development, manufacturing, marketing, and distribution of in-vitro diagnostic (IVD) reagents within the People's Republic of China. Its comprehensive product portfolio encompasses IVD reagents designed for assessing male and female fertility, detecting parasite antibodies, and identifying the Epstein-Barr virus. Additionally, the company provides auxiliary reproductive supplies and equipment, alongside a range of healthcare products and nutritional supplements marketed under its 'Nutronic' brand, which are sold through both digital and physical platforms. Products are distributed directly to hospitals and medical institutions, as well as through a network of third-party distributors. The company was founded in 1992 and maintains its headquarters in Wan Chai, Hong Kong.
日内区间
当前HK$0.178
52周区间
当前HK$0.178
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（CNY） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 2828.2万 CNY | 2535.9万 CNY | 2462.9万 CNY | 2533万 CNY | 2612.7万 CNY |
| 销货成本 | 1051.3万 CNY | 828.7万 CNY | 853.6万 CNY | 841.6万 CNY | 967.1万 CNY |
| 毛利 | 1776.9万 CNY | 1707.2万 CNY | 1609.3万 CNY | 1691.4万 CNY | 1645.6万 CNY |
| 研究与开发 | 392.5万 CNY | 282.5万 CNY | 255.3万 CNY | 248.3万 CNY | 243.7万 CNY |
| 销售、一般及管理费用 | 2147万 CNY | 1925.8万 CNY | 1849.1万 CNY | 1875.4万 CNY | 1769.9万 CNY |
| 营业费用 | 2633.6万 CNY | 2208.3万 CNY | 2348.4万 CNY | 2200.4万 CNY | 2103.4万 CNY |
| 利息收入 | 31.56万 CNY | 51.2万 CNY | 40.4万 CNY | 40.9万 CNY | 17.9万 CNY |
| 利息支出 | 23.96万 CNY | 8.6万 CNY | 5.3万 CNY | 5.5万 CNY | 10.2万 CNY |
| 折旧和摊销 | 371.6万 CNY | 333.4万 CNY | 317.9万 CNY | 314万 CNY | 294.9万 CNY |
| 营业利润 | −781万 CNY | −568.8万 CNY | −739.1万 CNY | −509万 CNY | −432.95万 CNY |
| 净利润 | −500.6万 CNY | −415.8万 CNY | −578.2万 CNY | −307.5万 CNY | −422万 CNY |
公司数据更新于 2026年10月16日。
近期已公布业绩
近期已公布业绩
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
